Harvard Heart Letter

Heart Beat: Osteoporosis drugs not linked to atrial fibrillation

An FDA review of trials involving bisphosphonate drugs used to treat osteoporosis found no link between their use and any increased risk of atrial fibrillation.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In